| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $4.1M | -71.1% |
| SG&A Expense | $12.2M | -10.5% |
| Operating Income | -$12.8M | -117.5% |
| Pre-tax Income | -$39.2M | -193.4% |
| Income Tax | $0 | — |
| Net Income | -$39.2M | -193.4% |
| EPS (Basic) | -$3.95 | -105.1% |
| EPS (Diluted) | -$3.95 | -105.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $3.0M | — |
| Current Assets | $3.4M | +113.7% |
| Total Assets | $5.6M | +77.0% |
| Current Liabilities | $6.9M | -51.3% |
| Total Liabilities | $60.6M | +91.1% |
| Stockholders' Equity | -$55.0M | -92.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$17.3M | +14.7% |
| Capital Expenditures | $4K | — |
| Investing Cash Flow | -$4K | — |
| Financing Cash Flow | $20.3M | +34.1% |
| Free Cash Flow | -$17.3M | — |